The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted ...

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells ...

Cryo-Cell (CCEL) announced that its board of directors has approved the payment of a regular quarterly cash dividend at an initial rate of 25c per share of common stock to be paid to its shareholders ...

Reports FY24 revenue $32M vs $31.3M last year. David Portnoy, Cryo-Cell’s (CCEL) Chairman of the Board and Co-CEO remarked, “The Company’s 2024 fiscal results were impacted by continued investments ...

Cryo-Cell International (CCEL) on Thursday said it received a notice from NYSE American stating the company is not in compliance with certain continued listing standards. The exchange cited the ...

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written ...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...

The Company reported net income of approximately $283,000 or $0.03 per basic and diluted common share for the three months ended February 28, 2025, compared to net income of approximately $556,000, or ...